A5083943881- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Heart Rate Variability and Autonomic Control
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Cardiac Structural Anomalies and Repair
- ECG Monitoring and Analysis
- Cardiac pacing and defibrillation studies
- Esophageal and GI Pathology
- Cardiac Arrhythmias and Treatments
- Congenital Heart Disease Studies
- Anorectal Disease Treatments and Outcomes
- Renal cell carcinoma treatment
- Surgical site infection prevention
- Acute Myocardial Infarction Research
- Surgical Sutures and Adhesives
- Atrial Fibrillation Management and Outcomes
- Colorectal and Anal Carcinomas
- Aortic Disease and Treatment Approaches
Kyushu University
2013-2025
Hamanomachi Hospital
2019-2023
Johns Hopkins University
2017-2022
Cancer Research Center
2017-2021
Deutschen Konsortium für Translationale Krebsforschung
2020
Johns Hopkins Medicine
2017-2019
Fujieda Municipal General Hospital
2019
Breast Cancer Care
2019
Toho University
2016-2017
Kyushu University Hospital
2015
Purpose Deleterious germline mutations contribute to pancreatic cancer susceptibility and are well documented in families which multiple members have had cancer. Methods To define the prevalence of these patients with apparently sporadic cancer, we sequenced 32 genes, including known DNA prepared from normal tissue obtained 854 ductal adenocarcinoma, 288 other periampullary neoplasms, 51 non-neoplastic diseases who underwent resection at Johns Hopkins Hospital between 2000 2015. Results...
To compare the risk of neoplastic progression by germline mutation status versus family history without a known (familial risk) among individuals with an increased for pancreatic cancer who are undergoing surveillance.Of 464 high-risk in Cancer Pancreas Screening program at Johns Hopkins Hospital were surveillance, 119 had deleterious susceptibility gene; 345 met criteria surveillance but not to harbor mutation. We used next-generation sequencing identify previously unrecognized mutations...
In Brief Objectives: To clarify the recurrence pattern after resection of main duct intraductal papillary mucinous neoplasms (MD-IPMNs) using molecular analyses and determine most adequate treatment strategy. Background: The appropriate line for MD-IPMNs remains an unresolved issue. Methods: Medical records 56 patients with pancreatectomy were retrospectively reviewed. Histological subtypes Kras/GNAS mutations assessed in remnant pancreas. Results: Forty-nine underwent partial 7 total...
The 2012 international consensus guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) pancreas stratified patients into 2 clinical categories, "high-risk stigmata" and "worrisome features," recommended different therapeutic strategies these groups. aim this study was to elucidate significance categories in terms predicting malignant IPMNs.The medical records 100 consecutive who underwent pancreatectomy IPMNs were retrospectively reviewed. Seventy with branch duct...
To evaluate whether germline variants in genes encoding pancreatic secretory enzymes contribute to cancer susceptibility, we sequenced the coding regions of CPB1 and other known pancreatitis susceptibility (PRSS1, CPA1, CTRC, SPINK1) a hospital series cases controls. Variants CPB1, CPA1 (encoding carboxypeptidase B1 A1), CTRC were evaluated second set with familial More deleterious variants, defined as having impaired protein secretion induction endoplasmic reticulum (ER) stress transfected...
Purpose: Pancreatic cysts are common and pose diagnostic management challenges. cyst fluid markers have the potential to aid in of with concerning imaging findings. Our aim was evaluate methylated DNA for their accuracy predicting histologic grade neoplastic pancreatic cysts.Experimental Design: samples from 183 patients (29 discovery 154 validation) aspirated after surgical resection were analyzed at selected genes (SOX17, BNIP3, FOXE1, PTCHD2, SLIT2, EYA4, SFRP1) using methylation-specific...
Objective: To identify factors predicting the development of high-risk lesions in remnant pancreas after surgery for intraductal papillary mucinous neoplasm (IPMN). Background: IPMN has unique features, including multifocality, adenoma-carcinoma sequence, and distinct pancreatic ductal adenocarcinoma (PDAC) same pancreas. Careful attention should, therefore, be paid to metachronous occurrence lesions, high-grade dysplasia or invasive carcinoma (HGD/INV) concomitant PDAC partial...
Purpose: The measurement of mutations in pancreatic juice samples collected from the duodenum during endoscopic ultrasound (EUS) may improve diagnostic evaluation patients undergoing surveillance. Our aim was to evaluate accuracy using mutation concentrations predict presence and histologic grade neoplasia pancreas.Experimental Design: Digital next-generation sequencing (NGS) DNA a targeted 12-gene panel performed on 67 EUS, including with ductal adenocarcinoma, who subsequently underwent...
Objective The aims of this study were to investigate the GNAS mutational status in pancreatic intraductal papillary mucinous neoplasm (IPMN) with and without distinct ductal adenocarcinoma (PDAC) evaluate significance analysis using duodenal fluid (DF) patients IPMN. Methods clinicopathologic features 110 IPMN including 16 PDAC reviewed. tissue 23 DF specimens was assessed by sensitive mutation scanning methods. Results rate significantly lower than that (4/16, 25%, vs 61/94, 65%; P =...
Levels of carcinoembryonic antigen (CEA), carbohydrate 19-9 (CA19-9), and cancer 125 (CA-125) in blood are used as markers to determine the response patients with therapy, but not identify pancreatic cancer.We obtained samples from 504 undergoing surveillance 2002 through 2018 who did develop measured levels tumor CA19-9, CEA, CA-125, thrombospondin-2. Single-nucleotide polymorphisms (SNPs) FUT3, FUT2, ABO, GAL3ST2 that have been associated were establish SNP-defined ranges for each marker....
To obtain a better understanding of the genetic alterations high-grade pancreatic intraepithelial neoplasia (HG-PanIN), we performed whole-genome copy number analysis by using single nucleotide polymorphism microarrays and targeted next-generation sequencing 11 microdissected HG-PanIN two low-grade PanIN lesions associated with HG-PanIN. mutation profiles were compared those their invasive ductal adenocarcinoma. All harbored somatic KRAS mutations. The most common losses in at CDKN2A (9p21),...
Objectives To clarify the usefulness of molecular biomarkers for distinguishing invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs [Inv-IPMN]) concomitant pancreatic ductal adenocarcinoma (PDAC). Methods Data 19 patients with resected PDAC were retrospectively reviewed. KRAS/GNAS mutations and immunohistochemical (IHC) expression p53 p16/CDKN2A assessed in both IPMN distinct PDAC. As controls, IHC labeling between noninvasive components 1 lesion 22 independent...
Objective: To clarify clonality of distinct multisegmental main duct (MD)-intraductal papillary mucinous neoplasms (IPMNs) using microarray analysis. Background: IPMNs represent a pancreatic ductal cell field defect, which causes multiple occurrences lesions. In addtion, it has been speculated that MD-IPMNs display features monoclonal skip progression. Methods: Total RNA was extracted from fresh-frozen tissue samples metachronous and nonneoplastic pancreas the same two individuals, whole...